The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation
Abstract
Our recent analyses of the cholesterol biosynthetic pathway in Huntington's disease (HD) cells, in the R6/2 huntingtin-fragment mouse model of HD as well as in human tissues have provided the first evidence of altered activity of this pathway in genetically identifiable HD samples. Here we report that these changes also occur in the full-length-huntingtin YAC128 (yeast artificial chromosome) mouse model, which shows a consistent reduction in the activity or levels of multiple components of the cholesterogenic pathway. We also show that this phenotype is progressive and is specific for the brain region most affected in HD. Mice over-expressing the wild-type protein with 18 CAG (YAC18 mice) show the opposite phenotype with higher activity of the cholesterol biosynthetic pathway compared with littermate mice. Finally, we report that plasma levels of cholesterol, its precursors and its brain-derived catabolite 24-S-hydroxycholesterol in YAC mice mirror brain biosynthetic levels supporting further investigation of their potential as peripheral biomarkers in HD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Cholesterol biosynthesis is severely reduced in the brain of HD mouse models, with the striatum affected first.
“A large number of studies conducted in different HD rodent models have demonstrated significantly reduced biosynthesis of cholesterol in the brain, with the striatum being affected first 17,18,19,20,21 .”
From SREBP2 gene therapy targeting striatal astrocytes ameliorates Huntington’s disease phenotypes (2021) · cites this paper as [19]
Steady-state levels of lanosterol, lathosterol, and desmosterol were reduced in the striata of R6/2-Tom mice compared with wt-Tom mice.
“As expected, the steady-state levels of all cholesterol precursors were reduced in the striata of R6/2-Tom mice compared with wt-Tom mice (Fig. 2H-J) 19,20,27,28 .”
From SREBP2 gene therapy targeting striatal astrocytes ameliorates Huntington’s disease phenotypes (2021) · cites this paper as [19]
Citations
Cites
High cholesterol level is essential for myelin membrane growth
Saher, G., Brügger, B., Lappe-Siefke, C., Möbius, W., Tozawa, R.-I., Wehr, M. C., Wieland, F., Ishibashi, S., & Nave, K.-A. (2005) · Nature Neuroscience · doi:10.1038/nn1426 · Cited by 799
Cholesterol homeostasis and function in neurons of the central nervous system
Pfrieger, F. W. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3018-7 · Cited by 453
Lund, E. G., Xie, C., Kotti, T., Turley, S. D., Dietschy, J. M., & Russell, D. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303415200 · Cited by 421
Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain
Lütjohann, D., Brzezinka, A., Barth, E., Abramowski, D., Staufenbiel, M., von Bergmann, K., Beyreuther, K., Multhaup, G., & Bayer, T. A. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200071-jlr200 · Cited by 158
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
HDL and cholesterol handling in the brain
Vitali, C., Wellington, C. L., & Calabresi, L. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu148 · Cited by 254
Evidence for altered cholesterol metabolism in Huntington's disease post mortem brain tissue
Kreilaus, F., Spiro, A. S., McLean, C. A., Garner, B., & Jenner, A. M. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12286 · Cited by 92
Segatto, M., Leboffe, L., Trapani, L., & Pallottini, V. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140303142902 · Cited by 65
SREBP2 gene therapy targeting striatal astrocytes ameliorates Huntington’s disease phenotypes
Birolini, G., Verlengia, G., Talpo, F., Maniezzi, C., Zentilin, L., Giacca, M., Conforti, P., Cordiglieri, C., Caccia, C., Leoni, V., et al. (2021) · Brain · doi:10.1093/brain/awab186 · Cited by 48
Self-citationStatins: Neurobiological underpinnings and mechanisms in mood disorders
Walker, A. J., Kim, Y., Borissiouk, I., Rehder, R., Dodd, S., Morris, G., Nierenberg, A. A., Maes, M., Fernandes, B. S., Dean, O. M., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.07.012 · Cited by 33
Metadata
- Authors
- Valenza, M., Carroll, J. B., Leoni, V., Bertram, L. N., Bjorkhem, I., Singaraja, R. R., Di Donato, S., Lutjohann, D., Hayden, M. R., & Cattaneo, E.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-27
- Volume
- 16
- Issue
- 18
- Pages
- 2187-2198
- ISSN
- 0964-6906
- 1460-2083
- Cited by
- 115
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review